Browse drugs

…tratumoral clustering of proliferating CD8+ T cells.Conclusions MDX2004 is a novel multispecific immune rejuvenator that induces robust…

…r rechallenge.Methods Two novel protein vaccines (TAT-PD-PR and DTT-PD-PR) with transactivator of transcription peptide (TAT) or diphther…

…or the treatment of OX40+ sarcoma and other solid tumors, where HX111 could potentially be a candidate treatment, warranting further …

…tases and resensitized tumors to anti-PD1 therapy. Importantly, PLT012 treatment not only elicited remarkable tumor-control immunity, …

….Conclusions These results highlight the potential of targeting DKK1 in combination with ICI therapies, to enhance NK cells activati…

…responses were associated with favorable clinical outcomes with ipilimumab.4 Tertiary lymphoid structures (TLS) are aggregates of T cells,…

…ly upregulated in the aPD-1 + microbubble condition compared to aPD-1 treatment alone (figure 1).Conclusions Our preclinical results …

…remained disease-free in the bone marrow (figure 2).Conclusions CLEC2A is a novel, leukemia-specific immunotherapeutic target that is …

…g the plethora of challenges raised by solid tumors.Conclusions TK-6302 demonstrates a favorable preclinical safety profile and robust …

…F-β individually, in both FaDu and 4T1 tumor models.Conclusions HCB301 represents a novel therapeutic approach that simultaneously tar…

…vity and systemic safety of Y101S were assessed in vivo.Results MSA-2 combined with YM101 significantly inhibited tumor growth and im…

…g immunosuppressive regimens comprising various combinations of sirolimus, everolimus, prednisone, cellcept, cyclosporine, tacrolimus, be…